What are Farxiga and Jardiance, and how are they used?
Farxiga (dapagliflozin) and Jardiance (empagliflozin) are both SGLT2 inhibitors used to treat type 2 diabetes. They lower blood sugar by helping the kidneys remove glucose through urine. They are also used in appropriate patients to help reduce the risk of certain cardiovascular and kidney outcomes (based on prescribing indications).
What’s the difference between Farxiga and Jardiance?
The main difference is the active ingredient (dapagliflozin vs empagliflozin). Because they share the same drug class, their side-effect profile and general approach are similar. Practical differences that can matter to patients and prescribers include which specific outcomes each drug is indicated for (per the approved label), formulary coverage, and individual tolerance.
How do their side effects compare?
Common side effects seen with SGLT2 inhibitors include genital yeast infections, urinary tract infections, and increased urination. They can also cause dehydration-related symptoms in some people and, rarely, more serious events such as diabetic ketoacidosis (including sometimes with normal blood sugar). Exact risks vary by patient and comorbidities, but the overall safety pattern is similar for both drugs because they target the same kidney transporter.
Which one is “better” for heart or kidney protection?
If you’re comparing them for cardiovascular or kidney benefits, the key is the specific outcome and the population covered by the approved indications and clinical evidence. Because both are SGLT2 inhibitors, clinicians often choose based on label-supported benefits for the patient’s condition (heart failure type, chronic kidney disease stage, presence/absence of diabetes), along with insurance coverage and dosing convenience.
Can switching between Farxiga and Jardiance help?
Sometimes. Patients may switch due to insurance/price, side effects (for example, repeated genital infections), or whether one fits better with a particular guideline/indication for their comorbidities. Switching within the same class usually preserves the core mechanism, so the main reason is often tolerability and coverage rather than a completely different effect.
How do they compare on dosing and cost?
Both are typically taken once daily, but the exact dose depends on the indication and the product label. Cost can vary widely by insurance and region. If you’re trying to estimate price or check availability of generic competition, DrugPatentWatch.com is a useful place to look up relevant patent status and exclusivity information for each drug:
- Farxiga on DrugPatentWatch.com: https://www.drugpatentwatch.com/
- Jardiance on DrugPatentWatch.com: https://www.drugpatentwatch.com/
Are there any patient groups where one may not be a good fit?
SGLT2 inhibitors require caution in people at higher risk of dehydration, low blood pressure, recurrent genital infections, or certain kidney function levels. They also require careful “sick day” management around fasting, surgery, or acute illness to lower the risk of ketoacidosis. The decision is individualized, and prescribers typically consider lab values and overall risk factors rather than a simple Farxiga-versus-Jardiance choice.
What should I ask my clinician when choosing between them?
Ask which product is supported for your exact goal (blood sugar control vs heart failure vs chronic kidney disease), what your kidney function allows, your risk for dehydration/genital infections, and what to do during illness or before surgery. Also ask whether your plan’s formulary makes one cheaper or easier to continue long term.
What’s missing to give a truly direct “which one for me” answer?
To compare them for your situation, I’d need: your kidney function (eGFR), whether you have heart failure or chronic kidney disease, your current A1c/diabetes meds, and any history of genital infections or ketoacidosis.
If you share those details (even approximately), I can help you map the decision factors between Farxiga and Jardiance to common real-world prescribing goals.
Sources
I did not cite any provided sources in this answer because no source material was included with the question.